Ashvattha Therapeutics’ phase 1 trial of patient-administered subcutaneous doses of its anti-VEGF therapy have shown it to be safe and well tolerated in healthy subjects. “We are advancing this first-in-class therapy to enable patients the convenience of self-administration with an autoinjector up to once a month in the comfort of their home,” said Dr Jeffrey Cleland, head of Ashvattha Therapeutics.
Presenting trial data at ARVO, Dr Cleland said adverse events were limited to mild, transient injection site reactions, which will be addressed with injection method changes. The company plans to initiate a phase 2 study in wet AMD and DMO patients in the coming weeks, he said.
